Riskpilot← Back to searchSign inGet full accessXenixPharma AB
ABActiveOrg 5591871404Bockfjällsvägen 7Temporary employment agency activities and other human resource provisions · NACE 7820Est. 20180 employees
Revenue 2024
SEK 0
EBITDA margin
—
-106% vs 2023
Equity ratio
88.5%
Financial strength
Net profit 2024
SEK 36K
-95% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -20K | -106% |
| Net profit | SEK 36K | -95% |
| Total assets | SEK 1,7M | -7% |
| Equity | SEK 1,5M | +2% |
| Employees | 0 | — |
Legal name
XenixPharma AB
Org number
5591871404
Legal form
Aktiebolag
NACE code
7820 · Temporary employment agency activities and other human resource provisions
Founded
19 december 2018
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva apoteksverksamhet, konsultativ verksamhet samt headhunting inom läkemedelsindustrin, apotek och sjukvårdsanläggningar, äga och förvalta fastigheter, lös egendom samt bedriva handel med värdepapper och därmed förenliga verksamheter.
Address
Bockfjällsvägen 7
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 784 | — | 1 224 | 369 | 0 |
| Staff expenses | — | — | −22 | −5 | −0 |
| EBITDA | 63 | 0 | 1 088 | 315 | −20 |
| Depreciation & amort. | −13 | — | −13 | — | — |
| EBIT | 50 | 0 | 1 075 | 315 | −20 |
| Net financials | — | — | −0 | 17 | 65 |
| Profit before tax | 37 | 0 | 805 | 870 | 46 |
| Tax | −8 | — | −167 | −182 | −10 |
| Net profit | 29 | — | 638 | 688 | 36 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 310 | — | 1 634 | 1 837 | 1 716 |
| Equity | 108 | — | 795 | 1 483 | 1 519 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 102 | — | 301 | 355 | 198 |
| Total debt | 102 | — | 301 | 355 | 198 |
EBITDA margin
-1980000.0%
This company
15.8%
Market median
-12531746% vs market
20202024
Equity ratio
88.5%
This company
38.2%
Market median
+132% vs market
20202024
Return on equity
2.4%
This company
18.4%
Market median
-87% vs market
20202024
Net profit margin
3581600.0%
This company
8.1%
Market median
+44217184% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.13×
This company
0.62×
Market median
+79% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AN Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of XenixPharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ala Nordström | Chief Executive Officer | 0 companies |
| Souhaila Kurdi | Deputy Board Member | 0 companies |
| Zahra Hussein Ali | Deputy Board Member | 0 companies |